RNAi, miRNA and Epigenetics Agenda

Registration

Discovery of SDC2 Gene as a Methylation Biomarker and Utility Test in Serum-DNA for the Earlier Detection of Colorectal Cancer
Sungwhan An, CEO, Genomictree Inc, Korea South

With an increase in the global incidence of colorectal cancer there is a heightened need for the development of a convenient and high-quality non-invasive screening tests. Widespread use of colonoscopic screening has been limited by cost and low compliance. In the present study the outcome of detecting early stage tumors with SDC2 methylation test in serum DNA is promising enough for this test to be possibly a simple and robust tool to detect more cancers at the stage where treatment outcomes are excellent.

Genomic Analyses of Hormone Signaling and Gene Regulation
Edwin Cheung, Assistant Professor, Genome Institute of Singapore, Singapore

In my talk, I will show how my lab has applied novel high-throughput sequencing technologies to elucidate the chromatin organization of cancer cells upon hormone signaling, as well as the identification and characterization of novel factors required for nuclear hormone receptor transcriptional activity.

Coffee Break and Networking in the Exhibition Hall

CANCELLED - Epigenetic Disruption of Cell Signaling Regulation in Human Cancers
Qian Tao, Professor, The Chinese University of Hong Kong, Hong Kong

Summary to be Confirmed

Molecular Biologic Substaging of Gastric Cancer
Youg-Min Huh, Professor, Yonsei University, Korea South

The TMN staging system by integrating molecular information would  be classified by patient’s genomic trait, and thereby facilitate the biologically tailored treatment according to the unique biology of tumor.

Lunch and Networking in the Exhibition Hall

Poster Viewing Session

SAMiRNA RNAi Nanoparticle Prodrug Technology
Jeiwook Chae, Director of RNAi, Bioneer, Korea South

Topics of discussion include SAMiRNA’s flexibility to incorporate siRNA sequences against any disease target, as well as enhancement of its therapeutic potential as a delivery platform through the use of cell-type specific targeting ligands. These data suggest that SAMiRNA is the most unique and singularly effective RNAi prodrug system developed to date. Using this novel RNAi prodrug technology, Bioneer is currently advancing clinical development of pipeline programs in previously non-druggable diseases, including cancer and COPD, through partnerships with major global pharmaceutical companies.

Coffee Break and Networking in the Exhibition Hall

The Worldwide Market for MicroRNA and Epigenetics: Research, Diagnostics, and Therapeutics
Enal Razvi, Managing Director, Select Biosciences Inc, United States of America

Select Biosciences industry tracking of the microRNA and Epigenetic fields has focused on qualitative and quantitative market trends based on primary market analyses. We have also conducted extensive analysis of all the publications in these fields which allow us to track the evolution of research trends in this interrelated spaces. These market analyses have been recently published in the Select Biosciences MicroRNAs and Epigenetics 2012 Market Reports, and in this presentation I will present a snapshot of the research trends in microRNAs and Epigenetics and frame them into their potential utility as biomarker classes for the future.

Drinks Reception

Mechanisms of MicroRNA Regulation by Natural Products and their Therapeutic Potential for Human Cancer
Keitaro Hagiwara, Professor, National Cancer Center, Japan

Our recent study revealed that natural products up-regulated tumour-suppressive microRNA and Ago2, leading to the prevention and treatment of human breast cancer. Our results raise the possibility that the regulation of microRNA machinery by natural product is a novel strategy in RNAi therapy against human cancer.

Coffee and Networking in Exhibiton Hall

RNAi and Antisense Oligonucleotide in vivo Delivery for Therapeutic Applications
Dmitry Samarsky, SVP, Technology & Global Business , Olix Pharmaceuticals, Korea South

Presentation will review the challenge of in vivo delivery of the RNAi and antisense therapeutic oligonucleotides, and will offer examples of successful solutions.

Discovery and Characterization of a Novel Regulatory Gene of the miRNA Biogenesis Pathway: Implications in Cancer Drug Discovery
David Shum, Assay Development Specialist, Memorial Sloan-Kettering Cancer Center, United States of America

miRNA dysregulation are associated with many disease states and genes/pathways to modulating their biogenesis are highly sought after. I will present the discovery of several regulatory genes involved in the miRNA biogenesis and discuss their significance as potential druggable targets in cancer therapy.

Lunch and Networking in Exhibition Hall

Poster Viewing Session

Second Generation RNAi Triggers and their Therapeutic Applications
Dong-Ki Lee, CEO, Olix Pharmaceuticals, Korea South

In this presentation, several novel gene silencing siRNA structural variants developed in Prof. Lee’s laboratory will be introduced and discussed in light of the structural flexibility of RNAi machinery and therapeutic potentials.

Coffee and Networking in Exhibiton Hall